Tandem Investment Advisors Inc. Sells 22,967 Shares of Becton, Dickinson and Company $BDX

Tandem Investment Advisors Inc. reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 8.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 246,923 shares of the medical instruments supplier’s stock after selling 22,967 shares during the period. Becton, Dickinson and Company makes up approximately 1.8% of Tandem Investment Advisors Inc.’s portfolio, making the stock its 26th biggest position. Tandem Investment Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $47,920,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BDX. Activest Wealth Management boosted its holdings in shares of Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter worth $25,000. Steph & Co. boosted its holdings in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the period. Cornerstone Planning Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 139 shares during the period. Finally, Accredited Wealth Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 70 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Up 0.1%

NYSE BDX opened at $147.76 on Tuesday. The business’s 50-day moving average is $152.60 and its 200 day moving average is $177.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock has a market capitalization of $40.71 billion, a PE ratio of 37.41, a PEG ratio of 10.45 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BDX shares. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Barclays lifted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. TD Cowen decreased their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Finally, The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a report on Friday, April 10th. They issued a “neutral” rating and a $167.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $184.86.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.